Navigation Links
Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
Date:2/26/2008

ourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. CardioDynamics Provides 2007 Shareholder Meeting Update
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  MT Services LLC, a Lawsuit Settlement ... that U.S. District Judge Joseph Goodwin ... status meeting in hopes to resolve more than ... manufacturers who are involved in multidistrict litigations under ... going on for some time, and Judge Goodwin ...
(Date:4/25/2015)... Join us for a webinar at 12 ... Times using the Transcreener® ADP Assay , Register ... increasingly being incorporated into lead development efforts because longer ... increased therapeutic window and reduced side effects. Though ... such surface plasmon resonance, conjugation of drugs can affect ...
(Date:4/24/2015)... MN , April 24, 2015 /PRNewswire/ - BioAmber ... by Bayer MaterialScience as the supplier of bio-succinic ... innovative, bio-based polyurethanes for textile applications that Bayer ... MaterialScience has launched IMPRANIL ® eco, a ... content that reaches as high as 65%.  IMPRANIL ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
Breaking Biology Technology:Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 2Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 3BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2
... Genome,Sciences, Inc. (Nasdaq: HGSI ) announced today ... Phase 2 clinical trial of HGS-ETR1 (mapatumumab) in,combination ... therapy in patients with advanced non-small cell lung ... newly diagnosed with non-small cell,lung cancer have locally ...
... abuse treatment for teens and adults, HIGHLANDS RANCH, ... the expansion of its treatment services to,include a detox ... 17 as well,as adults, and the hospital has added ... dual diagnosis (substance abuse and,mental illness)., Teen suicide ...
... LifeCell,Corporation (Nasdaq: LIFC ), today announced ... 2008 financial guidance on Monday, January,7, 2008 at ... Executive,Officer, will host a conference call at 10:00 ... revenues and expected financial performance,for 2008., The ...
Cached Biology Technology:Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 2Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 3Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 4Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 5Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 6Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern 2
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... study sheds new light on the role of carbon dioxide ... that instead of sinking, carbon dioxide is often consumed by ... dimly lit area 100 to 1,000 meters below the surface. ... it can be stored and prevented from re-entering the atmosphere ...
... for understanding life. DNA replication remains difficult to investigate ... double-membrane nucleus. However, the process is far easier to ... 40 (SV40), the large T-antigen protein (T-ag) is responsible ... the origin of replication. SV40 T-ag can also cause ...
... against amyloid-beta, the protein that forms plaques in the ... the brain from damage in early stages of the ... Hospital (MGH) researchers finds that lack of a protein ... led to increased amyloid-beta deposits and earlier death in ...
Cached Biology News:Ocean's 'twilight zone' may be a key to understanding climate change 2Blocking immune cell action increases Alzheimer's-associated protein deposits 2Blocking immune cell action increases Alzheimer's-associated protein deposits 3
...
... 1 Block MBS Start up kit. Includes ... and choice of 1 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
For testing the AQUA technique on your MS instruments....
Biology Products: